(1) To assess the clinical utility of the adjusted global antiphospholipid syndrome score (aGAPSS) to predict new obstetric events during follow-up in primary obstetric antiphospholipid syndrome (POAPS) patients under standard-of-care treatment (SC) based on the use of low-dose aspirin (LDA) + heparin and (2) to study the risk of a first thrombotic event and to evaluate whether stratification according to this score could help to identify POAPS patients who would benefit from long-term thromboprophylaxis.
Methods
This is a retrospective, multicentre study. 169 women with POAPS were evaluated for the presence of a new obstetric event and/or a first thrombotic event during follow-up [time period: 2008–2020, median: 7 years (6–12 years)]. The outcomes of 107 pregnancies from these POAPS patients with SC were studied to evaluate relapses. Simple and multivariable logistic regression analyses were performed.
Results
Regarding obstetric morbidity, only triple positivity for antiphospholipid antibodies (aPLs) [OR = 8.462 (95% CI: 2.732–26.210); p < 0.0001] was found to be a strong risk factor independently associated with treatment failure. On the other hand, triple positivity for aPLs [OR=10.44 (95% CI: 2.161–50.469), p = 0.004] and an aGAPSS ≥7 [OR = 1.621 (95% CI: 1.198–2.193), p = 0.002] were independent risk factors associated with a first thrombotic event. LDA was marginally associated with a decrease in the risk of thrombosis only in patients with aGAPSS ≥ 7 (p = 0.048).
Conclusion
aGAPSS appears to be useful in predicting the occurrence of a first thrombotic event in POAPS patients, and these stratification of patients could be helpful in selecting patients who would benefit from thromboprophylaxis with LDA.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
2.
MeroniPLBorghiMOGrossiC, et al.Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?Nat Rev Rheumatol2018; 14: 433–440.
3.
GrisJCBouvierSMolinariN, et al.Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood2012; 119: 2624–2632.
4.
TonelloMCalligaroAFavaroM, et al.The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics. Arch Gynecol Obstet2021; 303: 455–461.
5.
DrozdinskyGHadarEShmueliA, et al.Obstetric antiphospholipid syndrome and long term arterial thrombosis risk. J Thromb Thrombolysis2017; 44: 371–375.
6.
de JesusGRSciasciaSAndradeD, et al.Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG Int J Obstet Gynaecol2019; 126: 656–661.
7.
Caliz CalizRDiaz Del Campo FontechaPGalindo IzquierdoM, et al.Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part II: obstetric Antiphospholipid Syndrome and Special Situations. Reumatol Clinica2020; 16: 133–148.
8.
Caliz CalizRDiaz Del Campo FontechaPGalindo IzquierdoM, et al.Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: diagnosis, evaluation and treatment. Reumatol Clin (Engl Ed)2020; 16: 71–86.
9.
De CarolisSTabaccoSRizzoF, et al.Antiphospholipid syndrome: an update on risk factors for pregnancy outcome. Autoimmun Rev2018; 17: 956–966.
10.
RuffattiATonelloMVisentinMS, et al.Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology2011; 50: 1684–1689.
11.
LatinoJOUdrySArandaFM, et al.Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus2017; 26: 983–988.
12.
UdrySLatinoJOBeliznaC, et al.A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. Immunologic Res2019; 67: 478–485.
13.
MekinianAVicautECohenJ, et al.[Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]. Gynecologie Obstetrique Fertilite Senologie2018; 46: 598–604.
14.
MekinianAAlijotas-ReigJCarratF, et al.Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. Autoimmun Rev2017; 16: 730–734.
15.
SciasciaSSannaGMurruV, et al.GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology2013; 52: 1397–1403.
16.
RadinMSchreiberKCostanzoP, et al.The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol2017; 240: 72–77.
17.
SilverRMParkerCBReddyUM, et al.Antiphospholipid antibodies in stillbirth. Obstet Gynecol2013; 122: 641–657.
18.
ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol2002; 99: 159–167.
19.
UludagOBektasMCeneE, et al.Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. J Thrombosis Thrombolysis2020.
20.
SciasciaSRadinMSannaG, et al.Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology2018; 57: 661–665.
21.
Fernandez MosteirinNSaez CometLSalvador OsunaC, et al.Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting. Lupus2017; 26: 1328–1332.
22.
LatinoJOUdrySWingeyerSP, et al.What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?Immunologic Res2018; 66: 577–583.
23.
OkuKAmengualOYasudaS, et al.How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores. Curr Rheumatol Rep2017; 19: 51.
24.
SciasciaSSannaGMurruV, et al.The global anti-phospholipid syndrome score in primary APS. Rheumatology2015; 54: 134–138.
25.
OkuKAmengualOBohgakiT, et al.An independent validation of the Global Anti-Phospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases. Lupus2015; 24: 774–775.
26.
SchreiberKRadinMCecchiI, et al.The global antiphospholipid syndrome score in women with systemic lupus erythematosus and adverse pregnancy outcomes. Clin Exp Rheumatol2021; 39: 1071–1076.
27.
RadinMCecchiISchreiberK, et al.Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score. Semin Arthritis Rheumatism2020; 50: 553–556.
28.
RadinMUgolini-LopesMRSciasciaS, et al.Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. Semin Arthritis Rheumatism2018; 48: 117–120.
29.
RuffattiATonelloMCavazzanaA, et al.Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res2009; 123: 482–487.
30.
RuffattiACalligaroAHoxhaA, et al.Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res2010; 62: 302–307.
31.
ForastieroRMartinuzzoM. The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome. Expert Rev Clin Immunol2015; 11: 1255–1263.
32.
PengoVBanzatoABisonE, et al.Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus2010; 19: 428–431.
33.
TincaniATagliettiMBiasiniC, et al.Thromboembolic events after fetal loss in patients with antiphospholipid syndrome: comment on the article by Erkan et al. Arthritis Rheumatism2002; 46: 1126–1127; author reply 1127.
34.
QuenbySFarquharsonRGDawoodF, et al.Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reproduction2005; 20: 1729–1732.
35.
TektonidouMGAndreoliLLimperM, et al.Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open2019; 5: e000924.
36.
ArnaudLMathianARuffattiA, et al.Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev2014; 13: 281–291.
37.
ForastieroRMartinuzzoMPomboG, et al.A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thrombosis Haemostasis2005; 3: 1231–1238.
38.
RuffattiADel RossTCiprianM, et al.Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis2011; 70: 1083–1086.
39.
ErkanDMerrillJTYaziciY, et al.High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheumatism2001; 44: 1466–1467.
40.
CerveraRKhamashtaMAShoenfeldY, et al.Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2009; 68: 1428–1432.
41.
Martinez-ZamoraMAPeraltaSCreusM, et al.Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. Ann Rheum Dis2012; 71: 61–66.
42.
TektonidouMGAndreoliLLimperM, et al.EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis2019; 78: 1296–1304.
